Can You Take TRT With an Enlarged Prostate?

Last verified: October 2026 · By the TRT Provider Guide Editorial Team · Educational research, not clinically reviewed · How we research

Last updated: October 5, 2026.

---

Usually, yes. An enlarged prostate (BPH) does not automatically rule out TRT. Current evidence is reassuring for carefully evaluated men with mild-to-moderate urinary symptoms. Severe symptoms are different: major trials often excluded those men, and the Endocrine Society recommends against starting TRT with severe lower urinary tract symptoms until the problem is evaluated.

That's the short answer. The longer one comes down to something most men have never been asked to measure: how much the prostate problem is actually affecting urination. Prostate size matters, but urinary symptom severity is often more useful for this decision.

This page is for you if: you have an enlarged prostate or BPH-type urinary symptoms such as a weak stream, getting up at night, or going often, and you're considering prescribed TRT for properly diagnosed testosterone deficiency or you're already taking it.

Get checked before TRT if: your urinary symptoms are severe or getting worse fast. The same goes for a concerning PSA result, a lump or hard area on a prostate exam, past urinary retention, or blood in your urine.

Get medical help right away if: you can't urinate at all. The same applies to fever and chills with painful, urgent urination, blood in your urine, or severe pain in your lower belly or urinary tract.

TRT Provider Guide is the independent decision resource for testosterone replacement therapy — helping U.S. adults understand how low testosterone is evaluated, compare online and local care models and providers, and choose the next step that fits their health needs, fertility plans, budget, state, and care preferences, with every material claim verified and dated.

This page is educational information, not medical advice. It can't diagnose low testosterone, BPH, urinary obstruction, or prostate cancer, and it can't decide whether TRT is right for you.

---

The quick answer, by situation

Your next step depends more on urinary symptom severity and prostate-risk findings than on prostate size alone. Mild-to-moderate symptoms are the best-studied range. Severe symptoms, urinary retention, or concerning prostate findings should move the decision to urology first.

Sources: Endocrine Society guideline, HHS June 2026 labeling announcement, TRAVERSE prostate-safety trial, NIDDK BPH guidance.

---

Can you take TRT with an enlarged prostate?

Answer: An enlarged prostate by itself doesn't rule out TRT. What changes the answer is whether low testosterone has been properly confirmed, how bad your urinary symptoms are, whether your prostate evaluation raises any concerns, and whether you have a monitoring plan.

Here's the thing most pages get wrong. They treat "enlarged prostate" as one condition. It isn't, at least not for this decision.

Prostate size and urinary symptoms are two different things. Your prostate wraps around the tube you urinate through, called the urethra. As it grows, it can squeeze that tube. But a large prostate can cause little trouble, while a smaller enlargement can cause significant symptoms. NIDDK notes that urinary symptoms do not always match prostate size.

So when a doctor tells you "your prostate is enlarged," that fact matters. But how much it is affecting your urination matters too.

BPH is not cancer

Benign prostatic hyperplasia (BPH) is the medical name for noncancerous enlargement of the prostate. MedlinePlus says BPH is not prostate cancer and does not itself increase your risk of getting prostate cancer.

BPH and prostate cancer can still occur in the same person, and some symptoms overlap. That is why prostate-risk assessment is a separate part of the TRT decision.

Sources: NIDDK, MedlinePlus.

---

How bad are your urinary symptoms?

Answer: Clinicians often use the International Prostate Symptom Score (IPSS) to grade lower urinary tract symptoms. Scores of 0–7 are mild, 8–19 moderate, and 20–35 severe. That matters because TRAVERSE excluded men with scores above 19, and the Endocrine Society calls severe LUTS a reason not to start TRT until the issue has been addressed.

The IPSS covers seven common urinary problems, including incomplete emptying, frequent urination, stop-start flow, urgency, weak stream, straining, and getting up at night to urinate.

The severity bands are used in the NICE lower urinary tract symptom guideline. The original AUA/IPSS questionnaire can also be accessed through the freely available PhenX Prostate Symptoms protocol.

Write down your symptom band. You will use it again when you get to the care-route section.

Sources: NICE CG97, TRAVERSE, Endocrine Society guideline.

---

Does TRT make an enlarged prostate worse?

Answer: For carefully selected men without severe urinary symptoms at baseline, the best randomized evidence does not show TRT worsening lower urinary tract symptoms. The limit is important: severe LUTS were often excluded, so the reassuring results should not be stretched to every man with BPH.

The evidence boundary is severe LUTS

Here's the part that matters: the strongest reassuring evidence does not fully answer the question for men with severe urinary symptoms. That is the honest limit.

What the biggest trial found

TRAVERSE was a large randomized testosterone trial. Its prostate-safety analysis included 5,204 men with hypogonadism and cardiovascular disease or increased cardiovascular risk. Men with a PSA above 3.0 ng/mL or an IPSS above 19 were excluded. The testosterone group used 1.62% testosterone gel; the comparison group used placebo.

During 14,304 person-years of follow-up, testosterone did not significantly increase:

• Acute urinary retention
• Invasive procedures for BPH
• New drug treatment for lower urinary tract symptoms
• Prostate biopsy
• High-grade prostate cancer
• Overall change in IPSS compared with placebo

High-grade prostate cancer occurred in 5 of 2,596 men in the testosterone group and 3 of 2,602 in the placebo group; the difference was not statistically significant. PSA increased more with testosterone, especially during the first year.

The catch is not hidden: TRAVERSE was a screened trial population. Its findings should not be treated as proof of safety for men with severe obstruction or higher-risk prostate findings.

Source: Bhasin et al., JAMA Network Open, 2023.

What reviews of many trials found

• A 2016 meta-analysis in European Urology pooled 14 randomized trials with 2,029 men. Changes in IPSS were similar with TRT and placebo.
• A 2024 network meta-analysis included 21 randomized trials with 2,453 participants. Overall, the authors did not find worsening of LUTS across transdermal, intramuscular, and oral TRT routes.
• A 2016 systematic review of 35 prospective trials found little support for a causal link between TRT and new or worsening LUTS, while also noting that many studies excluded men with severe symptoms.
• A 2022 randomized trial of 120 men with BPH, metabolic syndrome, and low testosterone found no difference in urinary symptom improvement between testosterone and placebo over 24 weeks. Total prostate volume increased modestly in the testosterone group, while adenoma volume did not show a significant increase.

Sources: Kohn et al., 2016, Yuan et al., 2024, Kathrins et al., 2016, Rastrelli et al., 2022.

The honest counterweight

One large observational study points in a less reassuring direction, and you should know about it.

Researchers using MarketScan insurance data studied 882,570 men with hypogonadism. During the first 2.5 years after diagnosis, testosterone therapy was not associated with a significant difference in receiving a BPH diagnosis. After 2.5 years, men receiving testosterone had a 32% higher hazard of receiving a BPH diagnosis. Among men who had BPH, testosterone therapy was not associated with a significant increase in BPH interventions.

That study can show an association, not prove that testosterone caused the extra diagnoses. People receiving TRT may also have more contact with health care and more opportunities to receive a diagnosis.

So here's the fair read. Randomized trials are reassuring about urinary symptoms and short-to-medium-term prostate events in screened men, while longer-term observational data leave a real question about BPH diagnosis over time. Monitoring still matters.

Source: Fendereski et al., Urology, 2025.

Can TRT shrink an enlarged prostate?

Don't count on it. Some studies report stable or improved symptom scores, but TRT is not a BPH treatment. If urination is the main problem, it needs its own evaluation and care.

---

Why does my testosterone label still warn about BPH?

Answer: Labels and evidence do not always update at the same time. In June 2026, FDA requested revisions to testosterone labeling after its review found that available trial data did not demonstrate worsening symptoms in men with mild-to-moderate BPH. Current posted labels for some products still carry older BPH warnings, so the label for the exact product you are prescribed still matters.

On June 18, 2026, HHS announced that FDA was requesting three major testosterone-label changes:

1. Remove the limitation stating that safety and effectiveness had not been established for age-related hypogonadism.
2. Revise prostate-cancer safety information. The requested wording would make metastatic prostate cancer the prostate-cancer contraindication.
3. Revise the BPH warning because available trial data did not demonstrate worsening symptoms in men with mild-to-moderate BPH. HHS said evidence remains limited in severe symptomatic disease.

Those were requested labeling changes. They did not make every existing label change on the same day.

So if you see an older BPH warning in a medication guide, do not assume the newer evidence erased it. Follow the current label for the exact product and the clinician's monitoring plan.

Testosterone also remains a Schedule III controlled substance in the United States and requires a valid prescription. Federal telemedicine rules do not remove state-law or professional-practice requirements.

Sources: HHS June 18, 2026, FDA Testosterone Information, Depo-Testosterone DailyMed, Xyosted DailyMed, DEA Drug Scheduling.

---

What we actually verified — October 2026

Checked on: October 4, 2026

Primary and authoritative sources checked:

• HHS's June 18, 2026 testosterone-labeling announcement
• FDA's Testosterone Information page
• Current Depo-Testosterone and Xyosted labeling on DailyMed
• Endocrine Society's 2018 clinical practice guideline and July 2026 TRT statement
• AUA testosterone-deficiency guideline
• TRAVERSE prostate-safety trial
• Major randomized-trial reviews of TRT and lower urinary tract symptoms
• MedlinePlus and NIDDK BPH guidance
• Current finasteride and dutasteride labeling
• DEA and Federal Register telemedicine materials

Confirmed:

• FDA requested revised BPH labeling in June 2026.
• FDA's review found no demonstrated worsening of symptoms in men with mild-to-moderate BPH, while evidence remains limited for severe symptoms.
• TRAVERSE excluded men with IPSS above 19 or PSA above 3.0 ng/mL.
• The Endocrine Society recommends against starting TRT with severe lower urinary tract symptoms.
• Current posted labels for Depo-Testosterone and Xyosted still contain BPH-related warnings.
• Testosterone remains Schedule III.
• The current federal temporary telemedicine extension runs through December 31, 2026, subject to all other federal and state requirements.

Still uncertain:

• Prostate outcomes over decades of TRT.
• How well trial results apply to men with severe obstruction or higher-risk prostate findings.
• When each testosterone product label will reflect FDA's requested June 2026 revisions.
• How any one person's urinary symptoms will respond.

---

The right TRT provider is not the same for every person — it depends on whether low testosterone has been properly evaluated, your symptoms and health history, your fertility plans, your state, your insurance or cash-pay preference, your treatment-format preference, your budget, and whether online or in-person care is the better starting point. Some situations belong with primary care, urology, endocrinology, reproductive urology, or urgent or emergency care when the symptoms warrant it. Because a general answer cannot resolve those for you, use TRT Provider Guide's Find My TRT Path tool to map your situation to the right care route and the questions to ask before you pay.

Know your symptom band but not sure where to start?
Map the care route that fits your situation →

Free and educational. You'll get a starting care route and a question list, not a diagnosis, medical clearance, or guarantee of a prescription.

---

When should you see a urologist before starting TRT?

Answer: A urologist should be involved before TRT when urinary symptoms are severe, a PSA or prostate exam is concerning, urinary retention has occurred, or the cause of symptoms is unclear. These findings are not all permanent "no's" to TRT; they mean the prostate or urinary problem needs proper evaluation first.

Here's the "check first" list and why each item is on it:

• Severe urinary symptoms (IPSS 20–35). The Endocrine Society recommends against starting TRT with severe lower urinary tract symptoms. Major trials often excluded these patients.
• PSA above 4 ng/mL, or above 3 ng/mL in a man at higher prostate-cancer risk, without further urologic evaluation. This is part of the Endocrine Society's recommendation against starting TRT without further evaluation.
• A prostate nodule or induration. The Endocrine Society also places this on the evaluate-first list.
• Past urinary retention, recurrent urinary infections, bladder stones, or kidney problems from obstruction. NIDDK lists these as possible BPH complications. Our editorial judgment is that a man with these complications should have urology involved before TRT is treated as a simple online-care decision.

If you're on this list, here's the path

1. Have the prostate or urinary problem evaluated.
2. Treat or monitor the BPH as your clinician recommends.
3. Reassess symptom severity.
4. Revisit TRT only after the higher-risk issue is understood.

An in-person clinician or urologist can also evaluate things a telehealth-only workflow cannot do remotely, such as a prostate exam, bladder scan, urine-flow assessment, or other testing when clinically indicated.

Red flags: urgent care, not a TRT question

Get medical help right away if you:

• Can't urinate at all.
• Have painful, frequent, urgent urination with fever and chills.
• See blood in your urine.
• Have severe discomfort or pain in your lower abdomen or urinary tract.

Sources: Endocrine Society guideline, NIDDK, MedlinePlus.

---

What should be checked before TRT if you have an enlarged prostate?

Answer: The work-up has two separate jobs. First, confirm that testosterone deficiency is actually present with compatible symptoms or signs and consistently low testosterone on appropriate repeat morning testing. Second, understand the prostate and urinary problem well enough to decide whether routine TRT care or urology-first care makes sense.

Job one: confirm low testosterone the right way

The Endocrine Society recommends diagnosing hypogonadism only when a man has symptoms or signs consistent with testosterone deficiency and unequivocally and consistently low testosterone. Its technical guidance calls for total testosterone measurements on two separate fasting mornings using an accurate assay.

The Society repeated that position in July 2026: symptoms alone are not a diagnosis, and appropriate testing still matters after the FDA's label-update request.

One low number isn't a diagnosis. Neither is a symptom quiz.

See how low testosterone is diagnosed and whether you need two low testosterone tests.

Sources: Endocrine Society guideline, Endocrine Society 2026 statement.

Job two: understand your prostate

• Your urinary symptom burden. Bring your IPSS score or a clear symptom history so your clinician has a baseline.
• PSA when appropriate. The AUA testosterone-deficiency guideline says PSA should be measured before TRT in men over 40. The Endocrine Society uses a shared-decision approach to prostate monitoring based on age and risk.
• A prostate exam when clinically indicated. A concerning nodule or induration changes the path.
• Your full medication list. NIDDK notes that some decongestants, antihistamines, tranquilizers, antidepressants, and diuretics can worsen BPH symptoms.
• Finasteride or dutasteride use. These medicines lower PSA and change how the result should be interpreted.

For the broader lab list, see What blood tests are required before TRT.

Sources: AUA Testosterone Deficiency Guideline, NIDDK.

---

Does TRT raise PSA, and how much is too much?

Answer: TRT can raise PSA, especially during the first year, but a PSA rise is not itself a prostate-cancer diagnosis. The pattern, baseline risk, repeat confirmation, and prostate findings matter. The Endocrine Society gives specific first-year triggers for urologic consultation rather than telling patients to interpret one result on their own.

A PSA rise isn't a cancer diagnosis. The Endocrine Society notes that transient PSA elevations can come from test variability, prostatitis, BPH, urinary infection, or prostate trauma. That is why its technical guidance says elevations should be confirmed before acting on them.

The exact prostate-monitoring plan should be individualized. Do not turn the numbers above into a self-diagnosis rule.

Source: Testosterone Trials PSA analysis, Endocrine Society guideline.

For follow-up bloodwork, see How often should you get bloodwork on TRT.

---

Can you take TRT with Flomax, finasteride, or tadalafil?

Answer: Men can be prescribed BPH medicines and TRT at the same time, but that does not make the combination automatically right for you. The most important prostate-monitoring issue is with finasteride and dutasteride because both can substantially lower PSA, so the clinician interpreting your result must know you take them.

The finasteride and dutasteride PSA issue

Current labeling says:

• Finasteride lowers serum PSA by about 50% within six months. For an isolated PSA after six months or more of treatment, the label says to double the value for comparison with normal ranges in untreated men.
• Dutasteride lowers serum PSA by about 50% within three to six months. For an isolated PSA after three months or more, the label says to double the value for comparison with normal values in untreated men.
• With either medicine, a confirmed increase from the lowest on-treatment PSA should be evaluated even if the number is still within the usual untreated range.

That is more precise than simply saying "double every PSA forever."

Sources: Finasteride DailyMed, Dutasteride DailyMed.

A strategy some clinicians have studied

A small randomized trial of 53 older men with hypogonadism and symptomatic BPH compared testosterone plus dutasteride with testosterone plus placebo for six months. Prostate volume and PSA fell in the dutasteride group relative to testosterone alone, while symptom scores improved in both groups.

That is a useful question for a urologist. It is not a reason to add dutasteride on your own.

Source: Page et al., Journal of Urology.

---

Does TRT cause prostate cancer if you have BPH?

Answer: Current randomized evidence has not shown a significant increase in prostate-cancer events from TRT in carefully screened men over the studied follow-up, but that is not proof of zero lifelong risk. BPH, PSA changes, and prostate cancer are three separate issues, and long-term prostate-cancer safety remains an evidence gap.

Keep these separate:

1. BPH is benign enlargement. It isn't cancer and does not itself increase prostate-cancer risk.
2. A PSA rise is a signal that may need evaluation. It is not a cancer diagnosis.
3. Prostate cancer is a separate condition with its own evaluation and treatment decisions.

In TRAVERSE, any prostate cancer occurred in 12 men in the testosterone group and 11 in the placebo group, and high-grade prostate cancer was also rare, with no statistically significant difference between groups.

The AUA guideline says patients should be informed that there is an absence of evidence linking testosterone therapy to the development of prostate cancer. HHS's June 2026 labeling announcement likewise said available clinical-trial and epidemiologic data have not generally shown an increased prostate-cancer risk, while emphasizing that existing studies may not be long enough to settle long-term risk.

If you have known or suspected prostate cancer, this is a different decision from uncomplicated BPH. Urology or oncology should lead it.

Sources: TRAVERSE, HHS June 2026, AUA Testosterone Deficiency Guideline, MedlinePlus.

---

What if urination gets worse after starting TRT?

Answer: Do not assume TRT is the cause, and do not stop or change your treatment on your own. Worsening frequency, urgency, weak stream, nighttime urination, or incomplete emptying can come from BPH, infection, bladder problems, other medicines, or treatment-related changes, so the right response depends on the cause and severity.

If this is you, the useful question is not "Did I ruin my prostate?" It is "What changed, and does this need routine follow-up, urology, or urgent care?"

Here's what to do:

1. Re-score your urinary symptoms or write down what changed from your baseline.
2. List anything new, including cold/allergy medicines or prescription changes. NIDDK notes that some medicines can worsen BPH symptoms.
3. Contact the clinician managing your TRT with the symptoms and timing.
4. Ask whether you need urine testing, PSA testing, bladder-emptying assessment, or urology evaluation.
5. Get urgent medical help if you cannot urinate at all, have painful urgent urination with fever/chills, see blood in your urine, or have severe lower abdominal/urinary pain.

What happens next is your clinician's call. The response can be different for infection, BPH progression, retention, medication effects, or a TRT-related change.

New urinary symptoms on TRT and not sure which care route comes first?
Build my next-step plan →

Sources: NIDDK, MedlinePlus.

---

Is online TRT okay if you have an enlarged prostate?

Answer: It can be reasonable for some men with mild, stable urinary symptoms, but the program still has to diagnose testosterone deficiency correctly and monitor the prostate issue appropriately. Severe, changing, or complicated urinary symptoms belong with a urologist or another in-person clinician first.

Under the current federal temporary rule, DEA-registered practitioners may prescribe Schedule II–V controlled substances through qualifying telemedicine encounters without a prior in-person medical evaluation through December 31, 2026, if all other federal and state requirements are met. That rule does not mean every provider can prescribe in every state or that telehealth is clinically appropriate for every case.

Source: DEA Fourth Temporary Extension, Federal Register rule.

What we found when we checked online programs

Disclosure: TRT Provider Guide may earn commissions from some providers discussed elsewhere on this site. We are not using a provider enrollment CTA in this section because an enlarged-prostate question should be resolved by clinical fit first. Our method is published in How We Review TRT Providers.

The public testing workflows we checked are not equivalent:

These are provider-stated public workflows, not proof that a specific patient received the service described. We did not enroll, complete checkout, receive treatment, test support response times, or inspect an assigned pharmacy.

For a man with BPH, the first question is not which logo is cheapest. It is whether the care process correctly confirms hypogonadism and recognizes when urinary or prostate findings need urology.

Not sure whether online TRT or urology should come first?
Use Find My TRT Path →

Provider sources checked: Male Excel starter test, Male Excel TRT process, Male Excel homepage, Hone TRT page, Hone Premium testing schedule, Hone Premium workflow, Taurus offer.

---

What should you ask before starting TRT with an enlarged prostate?

Answer: Any good visit should leave you clear on two things: why TRT is being considered and how your urinary and prostate risks will be watched. Bring a written list so neither gets lost.

Print or save this:

1. Have I actually met the criteria for testosterone deficiency, with compatible symptoms or signs and repeat morning testosterone tests?
2. How severe are my urinary symptoms?
3. Do my symptoms look like uncomplicated BPH, or do I need more evaluation?
4. Is PSA testing appropriate for me before treatment, and how will we interpret changes?
5. If I take finasteride or dutasteride, how will that change the way you read my PSA?
6. Do you want a prostate exam or urologist involved before TRT?
7. When will you recheck my blood count, testosterone, prostate symptoms, and PSA if appropriate?
8. What PSA change or urinary symptom would make you refer me to urology?
9. If my stream gets weaker or I start retaining urine, who do I contact?
10. If I may want biological children, how does that change the plan? Exogenous testosterone can suppress sperm production.

---

How we researched this page

Answer: We checked the current primary and authoritative sources instead of relying on clinic marketing or old warnings. The core evidence includes FDA/HHS's June 2026 label-update request, current DailyMed labeling, Endocrine Society and AUA guidance, TRAVERSE, peer-reviewed systematic reviews, and federal BPH guidance.

We follow our published method, How We Review TRT Providers. It keeps four kinds of claims apart:

• Verified facts
• Provider-stated facts
• Customer-experience signals
• Editorial judgment

What we didn't do: We didn't sign up as patients, complete provider checkout, take lab tests, receive medication, inspect an assigned pharmacy, or treat anyone. A clinician has not reviewed this version of the page. Forum discussions informed the questions people ask, not the medical claims.

---

Frequently asked questions

Does testosterone make an enlarged prostate worse?

For men without severe urinary symptoms at baseline, randomized trials generally have not found worsening lower urinary tract symptoms with TRT. TRAVERSE found no significant difference in symptom-score change, acute urinary retention, BPH procedures, or new BPH medication compared with placebo. Men with IPSS scores above 19 were excluded, so severe symptoms remain less certain.

Can TRT make my prostate bigger?

It can affect prostate volume in some studies, but size and symptoms do not move together in a simple way. A 2022 randomized trial found a modest increase in total prostate volume with testosterone without a significant worsening of urinary symptoms. TRT is not a treatment for BPH.

Can TRT shrink an enlarged prostate?

There is no good evidence that TRT should be used to shrink the prostate. Some men have stable or improved urinary symptom scores during treatment, but BPH still needs its own evaluation and treatment when symptoms are bothersome.

Does TRT raise PSA?

It can. In the Testosterone Trials, PSA increased by about 0.47 ng/mL on average over 12 months in testosterone-treated older men compared with 0.06 ng/mL on placebo. Individual changes vary, which is why baseline context and repeat confirmation matter.

Does a higher PSA on TRT mean prostate cancer?

No. BPH, prostatitis, infection, prostate trauma, and normal test variation can all affect PSA. A confirmed rise may need further evaluation, but PSA by itself is not a cancer diagnosis.

Can I take testosterone and finasteride together?

They can be prescribed together, but finasteride changes PSA interpretation. Current labeling says finasteride lowers PSA by about 50% within six months and gives specific instructions for establishing a new baseline and interpreting isolated values. Tell every clinician reviewing your PSA that you take it.

Can I take TRT with Flomax (tamsulosin)?

Tamsulosin and TRT can be prescribed to the same patient, but the combination does not make TRT automatically appropriate. Your prescriber still needs to confirm testosterone deficiency and assess the urinary problem.

What IPSS score is too high for TRT?

A score of 20–35 is considered severe. The Endocrine Society recommends against starting TRT with severe lower urinary tract symptoms, and TRAVERSE excluded men with scores above 19. That is a strong reason to have the urinary problem evaluated before TRT is started.

Is BPH a contraindication on the testosterone label?

BPH itself is generally handled as a warning/monitoring issue in current product labeling rather than a blanket prohibition. In June 2026, FDA requested revised BPH warnings because available trial data did not demonstrate worsening symptoms in men with mild-to-moderate BPH, while evidence remains limited in severe disease.

Can I get TRT online if I have an enlarged prostate?

Sometimes. The important questions are whether testosterone deficiency is diagnosed correctly, whether the urinary symptoms are mild and stable, whether prostate risk is assessed appropriately, and whether the provider has a real monitoring plan. Severe or complicated urinary symptoms should start with urology rather than a direct-to-TRT pathway.

Should I stop TRT if I'm told my prostate is enlarged?

Do not make that decision from prostate size alone, and do not change prescribed testosterone on your own. Tell the prescribing clinician about the finding and your urinary symptoms so they can decide whether monitoring, BPH treatment, urology evaluation, or a TRT change is appropriate.

Does an enlarged prostate mean I have prostate cancer?

No. BPH is noncancerous enlargement and does not itself raise your risk of prostate cancer. Some urinary symptoms can overlap with other prostate conditions, which is why evaluation matters.

Can I use TRT after BPH surgery?

Possibly. It depends on whether testosterone deficiency is properly diagnosed and on your current urinary and prostate status. Your urologist and the clinician managing low testosterone are the right people to make that decision together.

---

The bottom line

An enlarged prostate does not automatically close the door on TRT. In carefully selected men with mild-to-moderate urinary symptoms, the best randomized evidence has not shown that testosterone worsens lower urinary tract symptoms. FDA moved to update class labeling in June 2026 for the same reason.

The line to respect is severe urinary symptoms or concerning prostate findings. The Endocrine Society recommends against starting TRT with severe LUTS, and the largest modern prostate-safety trial excluded men with IPSS scores above 19 and PSA above 3.0 ng/mL.

Confirm low testosterone correctly. Tell the clinician about BPH medicines such as finasteride or dutasteride. Have a monitoring plan. And if your urinary symptoms are severe, you have had retention, or your prostate evaluation is concerning, start with a urologist.

Still not sure which TRT care route fits you? Use our free Find My TRT Path tool.

---

Sources

1. U.S. Department of Health and Human Services. HHS Announces Requested Updates to Testosterone Therapy Product Labels. June 18, 2026. https://www.hhs.gov/press-room/fda-requests-updates-testosterone-therapy-labeling.html
2. U.S. Food and Drug Administration. Testosterone Information. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/testosterone-information
3. DailyMed. Depo-Testosterone (testosterone cypionate) injection. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cfbb53d4-b868-4a28-8436-f9112eb01c39&version=25
4. DailyMed. Xyosted (testosterone enanthate) injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a3d204c-be26-49e0-8599-0ac12a272e81
5. Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. https://academic.oup.com/jcem/article/103/5/1715/4939465
6. Endocrine Society. Statement on Testosterone Replacement Therapy. July 16, 2026. https://www.endocrine.org/news-and-advocacy/news-room/2026/statement-on-testosterone-replacement-therapy
7. American Urological Association. Evaluation and Management of Testosterone Deficiency. https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline
8. Bhasin S, et al. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(12):e2348692. https://pubmed.ncbi.nlm.nih.gov/38150256/
9. Kohn TP, et al. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis. Eur Urol. 2016;69(6):1083–1090. https://pubmed.ncbi.nlm.nih.gov/26874809/
10. Yuan X, et al. Effect of testosterone replacement therapy on lower urinary tract symptoms: A systematic review and network meta-analysis. J Evid Based Med. 2024;17(3):490–502. https://pubmed.ncbi.nlm.nih.gov/39004879/
11. Kathrins M, et al. The Relationship Between Testosterone-Replacement Therapy and Lower Urinary Tract Symptoms: A Systematic Review. Urology. 2016;88:22–32. https://pubmed.ncbi.nlm.nih.gov/26616095/
12. Rastrelli G, et al. Testosterone does not affect lower urinary tract symptoms while improving markers of prostatitis in men with benign prostatic hyperplasia: a randomized clinical trial. J Endocrinol Invest. 2022;45(7):1413–1425. https://pubmed.ncbi.nlm.nih.gov/35298833/
13. Fendereski K, et al. The Impact of Testosterone Therapy on Benign Prostatic Hyperplasia in Hypogonadal Males. Urology. 2025;196:325–332. https://pubmed.ncbi.nlm.nih.gov/39550043/
14. Snyder PJ, et al. Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial. J Clin Endocrinol Metab. 2019;104(12):6238–6246. https://academic.oup.com/jcem/article/104/12/6238/5536620
15. Page ST, et al. Dutasteride Reduces Prostate Size and PSA in Older Hypogonadal Men With BPH Undergoing Testosterone Replacement Therapy. J Urol. 2011. https://pmc.ncbi.nlm.nih.gov/articles/PMC3353656/
16. DailyMed. Finasteride. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c8ed59a3-c5b2-3156-b781-5e514b79011b
17. DailyMed. Dutasteride. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c78d18cf-05df-4154-b2f9-39cc374ca9e3
18. NICE. Lower urinary tract symptoms in men: management (CG97). https://www.nice.org.uk/guidance/cg97/chapter/recommendations
19. MedlinePlus. Enlarged Prostate (BPH). https://medlineplus.gov/enlargedprostatebph.html
20. NIDDK. Enlarged Prostate (Benign Prostatic Hyperplasia). https://www.niddk.nih.gov/health-information/urologic-diseases/prostate-problems/enlarged-prostate-benign-prostatic-hyperplasia
21. Drug Enforcement Administration. Drug Scheduling. https://www.dea.gov/drug-information/drug-scheduling
22. Drug Enforcement Administration. DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care. Dec. 31, 2025. https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care
23. DEA/HHS. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. Effective Jan. 1 through Dec. 31, 2026. https://public-inspection.federalregister.gov/2025-24123.pdf
24. Male Excel. At-Home Male Hormone Panel & Testosterone Test. Accessed Oct. 4, 2026. https://maleexcel.com/treatments/male-hormone-test/
25. Male Excel. TRT Online. Accessed Oct. 4, 2026. https://maleexcel.com/treatments/TRT-online/
26. Hone Health. Online Testosterone Replacement Therapy. Accessed Oct. 4, 2026. https://honehealth.com/mens/testosterone-replacement-therapy/
27. Hone Health. Men's Lab Schedule on the Premium Plan. Accessed Oct. 4, 2026. https://help.honehealth.com/hc/en-us/articles/40162286881431-Men-s-Lab-Schedule-on-the-Premium-Plan
28. Taurus Meds. Testosterone Blood Test. Accessed Oct. 4, 2026. https://taurusmeds.com/pages/testosterone-blood-test